Breaking News, Promotions & Moves

Aurion Biotech Makes Strategic Investments in Manufacturing

Appoints Tim Largen as VP of manufacturing to drive cell therapy production strategy and direct collaborations with leading CDMOs.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, has appointed Tim Largen as vice president of manufacturing. Mr. Largen is based in Seattle and will lead strategy and development of Aurion Biotech’s global cell manufacturing capabilities. His role will include managing Aurion Biotech’s internal team and as a division of CorneaGen, Inc., working with external teams at Cognate BioServices, a Charles River co...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters